ETON trades 12.1% below Wall Street's consensus target of $66.67.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ETON achieves its forward estimates and maintains a stable P/E multiple of 54.7x. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 25, 2026, Eton Pharmaceuticals, Inc. (ETON) has a Wall Street consensus price target of $66.67, based on estimates from 7 covering analysts. With the stock currently trading at $59.49, this represents a potential upside of +12.1%. The company has a market capitalization of $1.63B.
Analyst price targets range from a low of $62.00 to a high of $70.00, representing a 12% spread in expectations. The median target of $68.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 7 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ETON trades at a trailing P/E of -349.9x and forward P/E of 54.7x. Analysts expect EPS to grow +181.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 PRAXPraxis Precision Medicines, Inc. | $7.9B | $281.79 | $603.83 | +114.3% | Buy | — | 18 |
 AVDLAvadel Pharmaceuticals plc | $2.1B | $21.64 | $21.43 | -1.0% | Buy | 28.3x | 14 |
 TLRYTilray Brands, Inc. | $455M | $4.07 | $65.01 | +1497.3% | Hold | — | 20 |
 MNPRMonopar Therapeutics Inc. | $595M | $88.84 | $126.00 | +41.8% | Buy | — | 14 |
 KALAKALA BIO, Inc. | $11M | $0.56 | $18.25 | +3158.9% | Buy | — | 9 |
 SLRXSalarius Pharmaceuticals, Inc. | $697790 | $0.74 | — | — | — | — | — |
 LNTHLantheus Holdings, Inc. | $6.5B | $99.72 | $104.48 | +4.8% | Buy | 18.4x | 19 |
 SUPNSupernus Pharmaceuticals, Inc. | $2.5B | $43.29 | $57.60 | +33.1% | Buy | 16.9x | 14 |
 CORTCorcept Therapeutics Incorporated | $12.7B | $118.51 | $125.33 | +5.8% | Buy | 57.5x | 26 |
 PAHCPhibro Animal Health Corporation | $1.4B | $33.93 | $28.00 | -17.5% | Buy | 11.0x | 14 |
Quick answers to the most common questions about buying ETON stock.
Eton Pharmaceuticals, Inc. (ETON) has a consensus 12-month price target of $66.67, implying 12.1% upside from $59.49. The 7 analysts covering ETON see moderate appreciation potential.
ETON has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 7 Buy/Strong Buy ratings. The consensus 12-month price target of $66.67 implies 12.1% upside from current levels.
At a forward P/E of 54.7034x, ETON trades at a premium valuation. The consensus price target of $66.67 (12.1% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $70 for ETON, while the most conservative target is $62. The consensus of $66.67 represents the median expectation. These targets typically reflect 12-month expectations.
ETON is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ETON stock forecast based on 7 Wall Street analysts shows a consensus price target of $66.67, with estimates ranging from $62 (bear case) to $70 (bull case). The median consensus rating is "Buy".
ETON trades at a forward P/E ratio of 54.7x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on ETON, with a "Buy" consensus rating and $66.67 price target (12.1% upside). 7 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ETON analyst price targets range from $62 to $70, a 12% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $66.67 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.